secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2022-05-13T23:59:59+00:00
Accession:  0001104659-22-060416
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics appoints David Jin as Interim Principal Financial Officer
-----------------------------------------------------------------------------

- David Jin, 32, appointed Interim Principal Financial Officer effective May 11, 2022.
- Jin also serves as Interim Principal Executive Officer and Chief Operating Officer.
- Jin is VP of Corporate Development at Fortress Biotech; prior roles include Barings, Sorrento Therapeutics, FBR & Co, IMS Health.
- No family relationships with directors or executive officers; no reportable transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922060416/0001104659-22-060416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922060416/tm2215290d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-060416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer